Citable company snapshot
Thermo Fisher Scientific's latest SEC-sourced 2026-06-27 period shows $11.99B in revenue and $1.74B in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| Revenue | Jun 27, 2026 | $11.99B | $11.01B | +9.0% |
| Gross Profit | Dec 31, 2019 | $3.04B | $2.76B | +9.8% |
| Operating Income | Jun 27, 2026 | $2.09B | $1.86B | +12.0% |
| Net Income | Jun 27, 2026 | $1.74B | $1.65B | +5.1% |
| Operating Cash Flow (computed) | Jun 27, 2026 | $2.13B | $1.19B | +78.3% |
| Free Cash Flow (computed) | Jun 27, 2026 | $1.68B | $816.00M | +105.3% |
Source: SEC EDGAR financial statements; period Jun 27, 2026; filed Jul 31, 2026; accession 0000097745-26-000144.
TMO company research is free during early access. All you need is an account, with no card required. The five showcase tickers (TSLA, NVDA, AAPL, AMZN, PLTR) and the macro dashboard stay open without one.
Continue research
Follow same-sector companies and source explainers connected to the overview view.
A factual guide to market capitalization, shares outstanding, public float, and why share-count definitions matter.
A factual guide to dividends, share repurchases, and how companies can return capital to shareholders.
A factual guide to book value, tangible book value, and balance-sheet net worth measures.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.